Advaxis, Merck to combine immunotherapies for prostate cancer
This article was originally published in Scrip
Executive Summary
Advaxis jumped 23.1% to $4 per share on 25 August after the company announced a second partnership to test its immunotherapy platform in combination with a programmed cell death-1 (PD-1) inhibitor, the Merck & Co biologic pembrolizumab (MK-3475).
You may also be interested in...
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.